Agree. This is inappropriate collateral damage. It really affects TEVA's oral drug in development, rather than Copaxone unless proven to be far superior to Copaxone. We've known for the last two years that the orals are coming (and have come), so there should be no direct negative on MNTA. Additionally, any possible negative for Copaxone is 2-4 years down the road.
You buy when stocks go on sale. Actually purchased TEVA in pre-market for a daytrade.
Market Data 
Markets 
AI
